Recent corporate updates and clinical announcements from Cardiff Oncology highlight the continued clinical evaluation of its lead asset, onvansertib, in combination with standard-of-care regimens for difficult-to-treat solid tumor cancers such as metastatic colorectal cancer. Financial disclosures confirm ongoing clinical trial progress, research updates presented at major medical oncology congresses, and disciplined cash management strategies.